Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Regeneron and Sonoma Bio partner to develop Treg cell therapies for autoimmune diseases

New partnership to advance autoimmune disease treatment. 

By Brian Buntz | March 28, 2023

Sonoma/RegeneronTreg cell therapies are at the forefront of a collaboration between Regeneron (Nasdaq:REGN) and privately-held Sonoma Biotherapeutics, as they work together to discover, develop, and commercialize novel therapies for autoimmune diseases. This partnership combines Regeneron’s VelociSuite technologies with Sonoma Biotherapeutics‘ expertise in gene-modified T cell (Treg) therapies.

Under the terms of the agreement, Regeneron will pay Sonoma Biotherapeutics $75 million upfront, including a $30 million equity investment. Sonoma also stands to receive an additional $45 million development milestone payment. The parties will equally co-fund research and development for product development and will equally split future commercial expenses and profits.

REGN shares were up half a point to $824.46 in midday trading after announcing the news.

Joint research focus on Treg cell therapies

The collaboration will focus on Treg cell therapies for the inflammatory bowel disease subtypes ulcerative colitis and Crohn’s disease. They will also work on two undisclosed indications. Regeneron has an option for a fifth indication. Regeneron will have the option to lead late-stage development and commercialization on all products globally. Conversely, Sonoma will retain rights to co-promote products in the U.S. Sonoma will retain full ownership of its lead cell therapy candidate, SBT-77-7101, and other programs in development.

Focus on autoimmune disease treatment

Treg cells play a vital role in maintaining immune system balance and promise a paradigm-shifting approach to treating autoimmune and inflammatory diseases. Emerging research indicates that enhanced that the cells work directly at the site of inflammation and may provide a durable response. The potential benefits of the cell therapy subtype include targeted treatment, fewer side effects and long-lasting remission. Potential risks, however, may involve complications related to immune suppression, infection and challenges in regulating Treg cell activity.

Dr. Jeff Bluestone, co-founder and CEO of Sonoma Biotherapeutics, expressed excitement about the collaboration in a press release, noting that the partnership brings together Regeneron’s technological and clinical strengths and Sonoma Bio’s exclusive Treg platform and research capabilities to create therapies that may restore immune system balance and potentially cure diseases.

Similarly, Dr. George D. Yancopoulos, president and chief scientific officer of Regeneron, conveyed his enthusiasm for the partnership, highlighting the promising potential of engineered Treg cell therapies and the combined expertise of both companies in advancing treatments for autoimmune and inflammatory conditions.

Competitive landscape and related moves

There have been some other recent deals involving Treg cell therapies in 2023. For example, Quell Therapeutics raised $156 million in an oversubscribed Series B financing to advance its pipeline and platform of multi-modular engineered Treg cell therapies for various indications, including organ transplantation, autoimmune diseases, and neuroinflammation. Another example is Coya Therapeutics, which strengthened its leadership team with the addition of Arun Swaminathan as chief business officer to lead its business development and corporate strategy for its allogeneic Treg cell therapy platform.

Additionally, Gilead Sciences (Nasdaq:GILD) and its cell therapy subsidiary, Kite Pharma, have been developing Treg-based therapies for autoimmune diseases, including colitis and multiple sclerosis. Similarly, Sangamo Therapeutics (Nasdaq:SGMO) acquired the biopharma TxCell SA in 2018, aiming to develop Treg-based therapies for inflammatory diseases.


Filed Under: Cell & gene therapy, Gastroenterology

 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE